SARS-CoV-2 Spike Trimer Protein, His Tag (XFG) (MALS verified)

사용자 리뷰
제품 번호/규격
가격
수량
SPN-S5229-100ug
$472.00
SPN-S5229-1mg
$2940.00
ETA of in-stock products:2 business days
총 항목 수 제품 금액$ 0

제품 세부정보

  • Synonyms

    Spike, S protein, Spike glycoprotein, S glycoprotein

  • Source

    SARS-CoV-2 Spike Trimer Protein, His Tag (XFG) (SPN-S5229) is expressed from human 293 cells (HEK293). It contains AA Val 16 - Pro 1213 (Accession # QHD43416.1 (T19I, R21T, T22N, A27S, S31P, S50L, V127F, G142D, F157S, R158G, K182R, R190S, L212I, V213G, L216F, H245N, A264D, I332V, G339H, R346T, K356T, S371F, S373P, S375F, T376A, R403K, D405N, R408S, K417N, N440K, K444R, V445R, G446S, N450D, L452W, L455S, F456L, N460K, S477N, T478K, N481K, E484K, F486P, N487D, Q493E, Q498R, N501Y, Y505H, E554K, A570V, T572I, D614G, P621S, H655Y, N679K, S680P, P681R, N764K, D796Y, S939F, Q954F, N969K, D1084G, P1143L)). The recombinant protein is expressed from human 293 cells (HEK293) with T4 fibritin trimerization motif and a polyhistidine tag at the C-terminus. Proline substitutions (F817P, A892P, A899P, A942P, K986P, V987P) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein.

    Predicted N-terminus: Val 16

    Request for sequence

  • Molecular Characterization

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 138.5 kDa. The protein migrates as 80-90 kDa and 100-110 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).

    The protein is designed as a trimer.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 0.1 M Sodium citrate, pH5.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

고객님도 확인한 상품

데이터 표시

  • SDS-PAGE

    Spike protein SDS-PAGE

    SARS-CoV-2 Spike Trimer Protein, His Tag (XFG) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    Spike protein SEC-MALS

    The purity of SARS-CoV-2 Spike Trimer Protein, His Tag (XFG) (Cat. No. SPN-S5229) is more than 90% and the molecular weight of this protein is around 510-560 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     Spike protein ELISA

    Immobilized SARS-CoV-2 Spike Trimer Protein, His Tag (XFG) (Cat. No. SPN-S5229) at 5 μg/mL (100 μL/well) can bind Human ACE2, Fc Tag (Cat. No. AC2-H5257) with a linear range of 0.2-4 ng/mL (QC tested).

    Protocol

사용자 리뷰
댓글 남기기

배경 소개

SARS‑CoV‑2 XFG, also known as the “Stratus” variant, is a recombinant Omicron lineage derived from LF.7 and LP.8.1.2, first detected in January 2025 in Southeast Asia2. It carries key spike mutations such as T22N, S31P, K182R, R190S, R346T, K444R, V445R, F456L, N487D, Q493E, and T572I, some linked to enhanced immune evasion. By mid‑2025, XFG spread to over 38 countries, becoming dominant in parts of India and the United States1. Neutralization studies indicate reduced antibody sensitivity compared to earlier Omicron subvariants, prompting its classification by WHO as a Variant Under Monitoring on 25 June 20251.

프론티어 진행

 
의약품 개발 진행
  • 영어 이름:

    Coronavirus spike glycoprotein

  • 카테고리:

  • 상장 의약품 수:

    15 상세

  • 임상 의약품 수:

    88 상세

  • 최고 개발 단계:

    Approved

연락하기
신약 후보물질 라이선싱
더 많이 알아보기
  • 기본 제품 정보
  • 제품 세부정보
  • 고객님도 확인한 상품
  • 데이터 표시
  • 사용자 리뷰
  • 배경
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호